Literature DB >> 30112175

Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia.

Shinji Ohtake1,2, Takashi Kawahara1,2, Yukari Ishiguro2, Teppei Takeshima2, Shinnosuke Kuroda2, Koji Izumi2, Hiroshi Miyamoto3, Hiroji Uemura2.   

Abstract

Oxidative stress is a primary cause of vascular endothelial damage. In the prostate, ischemia increases the levels of reactive oxygen species, growth factors and cytokines, and induces the development of angiogenesis, which results in cancer progression. The expression levels of an oxidative stress marker, 8-hydroxyguanosine (8-OHdG), were compared between prostate cancer and non-neoplastic prostate tissues. A prostate tissue microarray composed of 10 cases of prostatic adenocarcinoma and 70 cases of benign prostatic hyperplasia was immunohistochemically stained for 8-OHdG. All cases expressed 8-OHdG. The levels of 8-OHdG expression in prostatic cancer (30.0% moderate and 70.0% strong) were significantly higher than those in benign prostatic hyperplasia (71.4% moderate and 28.6% strong; (p<0.01). Notably, 8-OHdG is expressed more highly in prostate cancer tissues in comparison to benign prostate tissues.

Entities:  

Keywords:  8-hydroxyguanosine; benign prostatic hyperplasia; oxidative stress; prostate cancer; tadalafil

Year:  2018        PMID: 30112175      PMCID: PMC6090576          DOI: 10.3892/mco.2018.1665

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  16 in total

Review 1.  ROS-mediated DNA methylation pattern alterations in carcinogenesis.

Authors:  Qihan Wu; Xiaohua Ni
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats.

Authors:  Daisuke Gotoh; Kazumasa Torimoto; Yoshihiro Tatsumi; Shunta Hori; Atsushi Yamada; Makito Miyake; Yosuke Morizawa; Katsuya Aoki; Nobumichi Tanaka; Akihide Hirayama; Kiyohide Fujimoto
Journal:  Neurourol Urodyn       Date:  2017-08-07       Impact factor: 2.696

Review 3.  The correlation between metabolic syndrome and prostatic diseases.

Authors:  Cosimo De Nunzio; William Aronson; Stephen J Freedland; Edward Giovannucci; J Kellogg Parsons
Journal:  Eur Urol       Date:  2011-11-15       Impact factor: 20.096

4.  Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.

Authors:  Osamu Yokoyama; Akichika Ozeki; Nahoko Suzuki; Masahiro Murakami
Journal:  Int J Urol       Date:  2017-11-01       Impact factor: 3.369

5.  Tadalafil for male lower urinary tract symptoms improves endothelial function.

Authors:  Kazuhiko Fukumoto; Atsushi Nagai; Ryoei Hara; Tomohiro Fujii; Yoshiyuki Miyaji
Journal:  Int J Urol       Date:  2016-12-29       Impact factor: 3.369

Review 6.  The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment.

Authors:  H K Koul; B Kumar; S Koul; A A Deb; J S Hwa; P Maroni; A van Bokhoven; M S Lucia; F J Kim; R B Meacham
Journal:  Drugs Today (Barc)       Date:  2010-12       Impact factor: 2.245

Review 7.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

Authors:  H Cai; D G Harrison
Journal:  Circ Res       Date:  2000-11-10       Impact factor: 17.367

8.  Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.

Authors:  Veronica Shim; Mona L Gauthier; Daniel Sudilovsky; Kristin Mantei; Karen L Chew; Dan H Moore; Imok Cha; Thea D Tlsty; Laura J Esserman
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1.

Authors:  Rajnee Kanwal; Mitali Pandey; Natarajan Bhaskaran; Gregory T Maclennan; Pingfu Fu; Lee E Ponsky; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2012-07-25       Impact factor: 4.784

10.  Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH.

Authors:  Motoaki Saito; Panagiota Tsounapi; Ryo Oikawa; Shogo Shimizu; Masashi Honda; Takehiro Sejima; Yukako Kinoshita; Shuhei Tomita
Journal:  Sci Rep       Date:  2014-01-22       Impact factor: 4.379

View more
  4 in total

Review 1.  Targeting oxidative stress in disease: promise and limitations of antioxidant therapy.

Authors:  Henry Jay Forman; Hongqiao Zhang
Journal:  Nat Rev Drug Discov       Date:  2021-06-30       Impact factor: 84.694

Review 2.  Redox signaling at the crossroads of human health and disease.

Authors:  Jing Zuo; Zhe Zhang; Maochao Luo; Li Zhou; Edouard C Nice; Wei Zhang; Chuang Wang; Canhua Huang
Journal:  MedComm (2020)       Date:  2022-03-31

Review 3.  Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine - comprehensive effects of phytochemicals in primary, secondary and tertiary care.

Authors:  Alena Mazurakova; Marek Samec; Lenka Koklesova; Kamil Biringer; Erik Kudela; Raghad Khalid Al-Ishaq; Martin Pec; Frank A Giordano; Dietrich Büsselberg; Peter Kubatka; Olga Golubnitschaja
Journal:  EPMA J       Date:  2022-07-08       Impact factor: 8.836

Review 4.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.